A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease

Trial Profile

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Cerliponase alfa (Primary)
  • Indications Neuronal ceroid lipofuscinosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 05 Dec 2017 Primary endpoint (Motor and Language Changes) has been met as per the results presented at the 71st Annual Meeting of the American Epilepsy Society
    • 05 Dec 2017 Results assessing long term safety and efficacy presented at the 71st Annual Meeting of the American Epilepsy Society
    • 17 Nov 2017 Planned End Date changed from 23 Aug 2019 to 1 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top